$CBIO
If PD(L)1 x VEGF is real (and I think it is), then $CBIO is well undervalued (and that's not even taking into account the intriguing ADC picture).
Market taking notice, especially with a couple of base hits from $SMMT ivonescimab...
$ARWR v $IONS
Plozasiran:
- four injections a year v. 12
- very deep TG lowering, >90% below 500,
- proven Acute Pancreatitis reduction
- NNT of approx. 3 in prior-pancreatitis patients
- safety: little injection-site burden & no hepatic-fat signal.
Strong case for the best
$BBIO$xbi — $ALNY$IONS$AZN$NTLA
The data continue to accumulate for acoramidis — whether talking about improvements in renal health, improved cardiac structure, or all cause mortality.
And though the individual constituents or modes of action need further elucidation, at
$XBI
True. With $XBI, the longer your time horizon for ownership, often enough, the higher your probability that you’ll own a defunct ticker:
🎩 @RayneWothbaum
$XBI
It could have been Warsh-comment rate fears that fed the Friday pullback, sure.
But my guess is more prosaic if no more satisfying of an explanation:
With Biotech investing, these things just happen — sharp pullbacks, for no particular reason, are the other side of